Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 40

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 40
---
 going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue
a going concern.

Management’s
plan includes raising funds from the issuance and sale of its common stock via its ATM program and other funding transactions. However,
as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable
to the Company or will provide the Company with sufficient funds to meet its objectives. The Company’s financial statements do
not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification
of liabilities that may be required should the Company be unable to continue as a going concern.

    For the three months ended September 30, 

    (In thousands)  
    Change Increase (Decrease) 

    2025  
    2024  

    Operating Expenses: 

    Clinical Research 

    OVATION 2 and MRD Trials 
    $124  
    $418  
    $(294) 
     (70.3)%
  
    OVATION 3 Trial 
     400  
     -  
     400  
     -%
  
    PlaCCine Vaccine Phase 1 Trial 
     9  
     523  
     (514) 
     (98.3)%
  
    Other Clinical and Regulatory 
     436  
     800  
     (364) 
     (45.5)%
  
    Subtotal 
     969  
     1,741  
     (772) 
     (44.3)%
  
    Non-Clinical R&D and CMC 

    OVATION Program 
     724  
     199  
     525  
     263.8%
  
    PlaCCine Vaccine Program 
     -  
     598  
     (598) 
     -%
  
    Manufacturing (CMC) 
     206  
     755  
     (549) 
     (72.7)%
  
    Subtotal 
     930  
     1,552  
     (622) 
     (40.1)%
  
    Research and development expenses 
     1,899  
     3,293  
     (1,394)